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The convolution associated with memory is being resolved with advancement in
neuroscience. According to the concurrent assumptions, synaptic plasticity forms one
of the basis of memory formation, stabilization and strengthening. In Alzheimer’s disease
(AD), which is generally characterized by memory dysfunction, connections amongst
the cells in the brain are attenuated or lost leading to degeneration of neural networks.
Numerous attempts have been made to find new therapies for memory dysfunction with
increasing attention and investments being laid on herbal drugs. Many herbal plants and
extracts have already documented beneficial results when tested for antiamnesic effects.
Brahmi (Bacopa monniera) is one such common herbal drug, which is employed for a
long time in the Indian and Chinese medical system in order to treat several disorders.
Previous research has shown that Brahmi exerts many pharmacological effects including
memory boosting capacity in the treatment of Alzheimer’s disease and Schizophrenia,
exhibiting antiparkinsonian, antistroke, and anticonvulsant potentials. The present review
discusses the chemical constituents of Brahmi along with in vitro and in vivo studies
based on the pharmacological effects exerted by it. The efficacy of Brahmi in treating
various disorders has evoked sufficient research in recent years and now it is a time to
launch multiple clinical trials.
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INTRODUCTION
The significance of Brahmi (Bacopa monniera Linn.) in improving memory and learning skills was
first published in 1982 (Singh and Dhawan, 1982). Since then various studies have been conducted
in animals to determine various properties exhibited by themedicinal herb. The potential of Brahmi
in shielding neuronal structure and/or function has also been evaluated in a number of growing
studies. Brahmi is a well-known Ayurvedic medicinal herb, which is re-emerging as a recourse to
treatment of memory related disorders. Its medicinal potency is reported both in Indian as well
as Chinese traditional literature. Although many chemical compounds have been isolated from
Brahmi, the active fractions of this medicinal plant contain bacoside-A and bacoside-B. A number
of other phytochemicals such as alkaloids, glycosides, flavonoids, saponins etc. are the constituents
of Brahmi (Dutta and Basu, 1963; Chatterji et al., 1965; Basu et al., 1967).
Investigations conducted so far have revealed that Brahmi exerts many pharmacological
effects (Figure 1) including memory boosting effect in the treatment of Alzheimer Disease and
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Schizophrenia, besides displaying antiparkinson, antistroke, and
anticonvulsant potentials. The present review discusses the
chemical constituents of Brahmi together with in vitro and
in vivo studies based on its molecular and pharmacological effects
(Figure 1).
CHEMICAL CONSTITUENTS OF BRAHMI
Bacopa monniera is characterized by its typical chemical
composition which predominantly includes compounds like
dammarane-type triterpenoid saponins called as bacosides,
with jujubogenin or pseudo-jujubogenin moieties as their
aglycone units. Based on the structural similarity, 12 analogs
from the family of Bacosides have been elucidated. In the
recent past, bacopasides I–XII, a different class of saponins
have been identified as an important constituent of the
herbal extract (Rauf et al., 2013). Apart from hersaponin,
apigenin, D-mannitol, monnierasides I-III, plantainoside B and
cucurbitacin; the alkaloids brahmine, herpestine and nicotine
have also been classified in the chemical constituents of
Bacopa monniera. Bacoside A is the most studied and potent
constituent of Bacopa, which is composed of bacoside A3,
bacopasaponin C, bacopaside II and bacopaside X (Srivastava
et al., 2012; Deepak and Amit, 2013; Singh et al., 2014;
Figure 2).
Various research groups have separated the constituents of
Brahmi through HPLC. Several mobile phase systems have been
used for the purpose of separating various chemical constituents
of Brahmi likemethanol and water (Ganzera et al., 2004); mixture
of acetonitrile and 0.05M sodium sulfate (pH 2.3; 68.5:31.5;
Sivaramakrishna et al., 2005; Murthy et al., 2006); 0.25%
orthophosphoric acid in water and acetonitrile (Phrompittayarat
et al., 2007; Sumathi and Devaraj, 2009); but till now no
FIGURE 1 | Major pharmacological effects of Brahmi with respective
target molecules.
consensus mobile phase system has come up for the analysis of
Brahmi constituents.
ACTIVE COMPONENTS
The therapeutic effects of Bacopa monniera are believed to
be exerted through triterpenoid saponins present in the plant
extract. Bacosides are the triterpenoid saponins of prime
importance. They have been shown to enhance nerve impulse
transmission. The bacosides promote the repair of damaged
neurons by upregulating neuronal synthesis and kinase activity.
The bacosides also aid in the restoration of synaptic activity,
which ultimately leads to nerve impulse transmission (Singh
and Dhawan, 1997). The nerve impulse transmission, plays a
vital role in promoting healthy cognitive functions like attention
span, focus, concentration, learning and memory. There is
evidence which suggests that Bacopa, by the virtue of containing
active constituents like bacosides, influences the synthesis and
availability of the neurotransmitter, Serotonin; therefore, Bacopa
helps to maintain neurotransmitter balance (Charles et al., 2011;
Rauf et al., 2012a).
PHARMACOLOGICAL EFFECTS
Memory Booster in Alzheimer’s Disease
and Schizophrenia
Brahmi (Bacopa monniera) has been used in the form of
memory enhancer for many years. The accreditation of the
traditional assertion of Brahmi was initiated by investigating
the effect of an alcoholic extract of this herb on acquisition,
consolidation and retention in different conditioning schedules
in rats. These included shock driven brightness-discrimination
response, continuous avoidance and active conditioned response.
It was found that motor skills, acquisition and consolidation
were improved and newly acquired behavior was retained for
a long period of time in all the three learning responses by
the introduction of the CDRI-08 (KeenMind; 40mg/kg, po. ×
3d) in mice (Singh and Dhawan, 1982, 1997). To discern
the efficacy of Brahmi in causing the reversal of amnesia,
several behavioral studies have been conducted by inducing
amnesic agents in animals. Some of the potential amnesic agents
including benzodiazepines, scopolamine, quinoline derivatives
and phenytoin cause amnesia by interrupting long-term
potentiation (LTP). The process of LTP is probably interfered by
the involvement of gamma-aminobutyric acid-benzodiazepine
pathway. Saraf et al. demonstrated that amnesia induced by
diazepam (1.75mg/kg) was significantly reversed by Brahmi
(120mg/kg) which was provided orally in mice (Prabhakar
et al., 2008). Subsequently, the same group later examined
the influence exerted by Brahmi on the downstream signaling
molecules related to LTP in amnesic mice, which were developed
by diazepam (Saraf et al., 2008). The molecular tests revealed
that diazepam upregulated the gene expression of inducible
nitric oxide synthase (iNOS), mitogen activated protein kinase
(MAP kinase) and phosphorylated CREB (pCREB) whereas
reduced the expression levels of cAMP response element binding
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FIGURE 2 | Chemical constituents of Brahmi.
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protein (CREB), cyclic adenosine monophosphate (cAMP), total
nitrite and nitrate. The levels of calmodulin remained unaltered
with diazepam induction. On the contrary, administration of
Brahmi inhibited the increased expression of iNOS, pCREB and
MAP kinase molecules and restored nitrite level to normal, the
expression of which was altered by diazepam. The levels of
cAMP, total CREB, total nitrite, nitrate and PDE were found
to be unaffected by Brahmi. These behavioral findings provide
tempting conclusion that Brahmi reverses amnesia induced by
diazepam and can be used in the treatment of Alzheimer’s Disease
and Schizophrenia.
GABAergic and cholinergic system plays a vital role in
reversing the amnesic behavior shown by diazepam and
scopolamine. To assess the effect of Brahmi on downstream
signaling molecules, amnesia was induced in mice by
administrating of MK-801 and N(w)-nitro-L-arginine (L-NNA;
Saraf et al., 2009). MK-801 is a NMDA receptor antagonist
while L-NNA inhibits the production of nitric oxide that
eventually results in memory loss. Morris water maze scale
was selected to assess memory and learning skills in animals.
It was found that supplementation of both of the amnesic
agents in mice resulted in anterograde and retrograde amnesia
and that Brahmi significantly reversed the L-NNA induced
anterograde and retrograde amnesia. On the contrary,
exposure of MK-1 induced mice to Brahmi didn’t influence
anterograde and reterograde amnesia. This suggests that
Brahmi reverses the amnesic effect caused by L-NNA but not
with MK-1.
In yet another investigation, scopolamine was used to induce
amnesia in mice and the effect of Brahmi was investigated
on downstream signaling molecules (Saraf et al., 2010a). The
findings revealed that the levels of protein kinase C and
iNOS were downregulated whereas that of protein kinase A,
MAP kinase, cAMP, calmodulin, pCREB, CREB and nitrite
remained in normal range with the induction of scopolamine.
Brahmi overruled the effect of scopolamine in amnesic mice by
significantly increasing protein kinase C, calmodulin and pCREB
levels. This shows that Brahmi contributes to prevent memory
loss mediated by calmodulin. In addition, Brahmi is reported
to significantly reverse L-NNA induced anterograde amnesia
instead of MK-801 induced anterograde amnesia (Anand et al.,
2010). Moreover, Brahmi ameliorates spatial memory in amnesic
model of mice created using scopolamine (Saraf et al., 2011).
In this study, the investigating group tested the anti-amnesic
effect of Brahmi on amnesia induced by scopolamine using
Morris water maze test. Muscle coordination activity in the
animals was assessed using the rotarod test. The results revealed
that both anterograde and retrograde amnesia produced by
scopolamine were reversed by Brahmi treatment (Figure 3).
These observations were suggestive of Brahmi’s promising
potential in the development of alternate approaches in the
therapy of Alzheimer’s disease. Similarly, Brahmi ameliorated
memory impairment induced by phenytoin which further
provides evidence for its role as an antiamnesic agent (Vohora
et al., 2000). In addition, BN52021 which is a platelet-activating
factor receptor antagonist was used to induce retrograde amnesia
inmice was also ameliorated by Brahmi treatment. The reason for
this might be an increase in glutamate level in the brain, which
further increases platelet activating factor synthesis (Kishore
and Singh, 2005). Brahmi also plays a neuroprotective role
in rat by maintaining the level of mitochondrial enzymes,
which got deviated due to morphine induction (Sumathi et al.,
2011).
Recently, the neuroprotective effect of Brahmi was
investigated in a rat model of schizophrenia (Piyabhan and
Wetchateng, 2014). The authors evaluated discrimination ratio
as a measure of cognitive ability from novel object recognition
task. N-methyl-D- aspartate receptor subtype 1 (NMDAR1)
density was also measured in different areas of brain including
prefrontal cortex, striatum, cornu ammonis fields I (CA1) and
2/3 (CA2/3) of hippocampus and dentate gyrus (DG). The
findings revealed a significant reduction in discrimination
ratio in schizophrenia induced group compared to control.
NMDAR1 showed upregulated expression in CA2/3 and DG
but not in prefrontal cortex, striatum or CA1. Upon Brahmi
administration, the DR score increased up to normal with
considerable downregulation of NMDARI in CA2/3 and DG.
The mechanism for memory impairment in schizophrenia
induced rats appeared to be mediated by upregulation of
NMDAR1 in CA2/3 and DG areas of brain. Interestingly,
administration of Brahmi could restore this memory impairment
by decreasing NMDAR1 in these brain areas. Therefore,
Brahmi could be regarded as a novel frontier for the prevention
of memory impairment in schizophrenia. The same group
previously measured the vesicular glutamate transporter type 1
(VGLUT1) density in same areas of brain and found a significant
decrease in the expression of this transporter of rat model of
schizophrenia (Piyabhan and Wetchateng, 2013). As expected
administration of Brahmi upregulated the expression of this
transporter to normal level thereby proving its effectiveness
in the treatment of Schizophrenia. Brahmi also possesses anti-
epileptic property as evidenced by reducing the dopamine levels
of dopaminergic neurons in the frontal cortex region of the rat
brain (Jash and Chowdary, 2014). These observations suggest
that Brahmi may possess the property to alleviate the positive
symptoms of schizophrenia.
Khan et al. demonstrated the therapeutic efficacy of Brahmi
on intellectual impairment and oxidative damage, induced by
streptozotocin in rat models (Khan et al., 2015). The data
showed that streptozotocin deteriorated memory and learning
skills in these animals, which were significantly improved by
Brahmi supplementation. Furthermore, increase in the amount
of thiobarbituric acid reactive substances, indicative of lipid
peroxidation, were visualized in the brain of these animals.
Antioxidant status was also found disturbed in the hippocampus
region of the brain along with a decrease in copper and
zinc concentration in these experimental animals. Brahmi
significantly ameliorated all of these alterations induced by
streptozotocin in rats. The data suggests that formation of free
radicals and increased rate of lipid peroxidation as a result
of streptozotocin induction might cause neurotoxicity in these
animals which can be prevented by the use of Brahmi. The
study demonstrates the usefulness of Brahmi for the treatment
of intellectually impaired patients.
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FIGURE 3 | Proposed schematic presentation of effect of B. monniera on acquisition and retrieval of memory. The diagram depicts that
scopolamine-induced impairment of acquisition and retrieval of memory are reversed by B. monniera pretreatment (Adapted from Saraf et al., 2011).
Brahmi has been reported to increase the level of serotonin,
trigger 5-HT3A receptors and CREB in hippocampus of
postpartum rats thereby facilitating its learning abilities (Rajan
et al., 2011). To identify the mechanism by which Brahmi
acts on sodium butyrate (NaB) induced rat pups, the animals
were subjected to fear conditioning test (Preethi et al., 2014).
Fear conditioning is a behavioral paradigm in which an
organism learns to envisage to an aversive stimulus. This
stimulus is associated with neutral stimulus that elicits a
state of fear response in the organism. The results revealed
that Brahmi treatment in NaB induced rats facilitated the
freeze response and triggered extracellular ERK/CREB signaling
transduction. The levels of HAT containing coactivators such
as p300, acetylated histones (e.g., Ac-H3 and Ac-H4) showed
up regulated expression whereas HDACs (1, 2) and protein
phosphatases (PP1α, PP2A) showed down regulated expression
in hippocampus after fear conditioning test. Subsequently,
the expression of brain-derived neurotrophic factor (Bdnf)
(exon IV) mRNA was found to be increased indicating that
Brahmi enhances hippocampus-dependent contextual memory
by modulating the expression of histone acetylated proteins and
protein phosphatases in hippocampus.
Antiparkinson’s Effects
Apart from alleviatingmemory, Brahmi is demonstrated to play a
role in treating Parkinson’s disease, which is a neurodegenerative
disorder marked by the loss of neurons which produce dopamine
in substancia nigra and alpha-synuclein protein, is accumulated
in the inclusion bodies known as lewy bodies (Feany and Bender,
2000). To study the mechanism underlying PD pathogenesis
various experimental models have been employed. However,
research on evaluating the effect of Brahmi and other plant
extracts in PD models is limited. Recently, Siddique et al.
investigated the effect of CDRI-08 (KeenMind) in transgenic
Drosophila fruit fly (PD model) which expressed normal human
alpha synuclein in their neurons. Different parameters including
climbing skills, activity pattern, oxidative stress and apoptosis
were measured to study the effect of Brahmi in the brain of fruit
fly. Their findings revealed an improved climbing ability as well
as activity pattern, reduced oxidative stress and apoptosis upon
exposure of flies to Brahmi. These findings were dose dependent
and suggest that the herb attenuates behavioral deformities,
reduces the oxidative stress and neuronal cell death in the brains
of PD model flies. Similar findings were obtained by Jansen et al.,
who also demonstrated the efficacy of Brahmi in alleviating the
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climbing activity of fruit flies compared to non-treated fruit flies
(Jansen et al., 2014).
In line with previous research Jadiya et al., employed
Caenorhabditis elegansmodel of Parkinson’s disease to investigate
the efficacy of this herb. Their findings revealed that Brahmi
exposure reduced alpha synuclein accumulation, prevented
dopaminergic cell death and restored the lipid content in
this PD model. These data provide an evidence for Brahmi
to be considered as a possible anti-Parkinsonian medication
and further research on the potential use of herbal plants,
compounds, and extracts in treating Parkinson’s disease is
required (Jadiya et al., 2011).
Antistroke Effects
The medicinal potency of Brahmi in treating Alzheimer’s Disease
and Parkinson’s Disease has already been established. To explore
its role in treating brain stroke, few investigations have been
conducted by Rehni et al., who explored the role of this herbal
plant on ischemia and reperfusion induced brain injury in
experimental mice (Rehni et al., 2007). Ischemic-reperfusion
induction lead to the increase in infarct size and impairment
of short-term memory and motor balance. On the other hand,
administration of Brahmi in these mice significantly reduced the
infarct size and attenuated their short-term memory and motor
balance. In line with this report, Saraf et al. investigated the role
of Brahmi in ischemic induced brain injury in rats. Brahmi was
supplemeted at a dosage of 120, 160, and 240mg/kg in these
animals and various behavioral and biochemical analysis were
done to screen the efficacy of this herb (Saraf et al., 2010b). Their
findings showed a protective role of Brahmi in reducing infarct
size in the ischemic brain and ameliorating memory dysfunction
as shown in the plus maze task. Additionally, administration of
Brahmi improved the muscle coordination and catalase activity
in rats exposed to ischemic insult. Levels of nitrite, nitrate
and rate of lipid peroxidation were also significantly decreased.
These observations indicate that Brahmi protects brain against
ischemia-induced insults and further research in this direction is
warranted.
Furthermore, brain ischemia reduces blood flow in cerebral
arteries due to the lack of oxygen supply. To investigate whether
Brahmi exerts any effect on cerebral blood flow (CBF) Kamkaew
et al., measured this parameter in rats (Kamkaew et al., 2013).
Rats were treated with a dose of 40mg of Brahmi for a period
of 8 weeks and thereafter, the CBF was measured via Doppler.
Interestingly, the herb was found to increase the cerebral blood
flow (CBF) by 25% in rats without affecting their blood pressure.
These findings further confirm the efficacy of this herb in the
treatment of neurological disorders and further research in this
direction is required.
Anticonvulsant Effects in the Treatment of
Epilepsy
Epileptic seizures represent a cardinal feature of the neurological
syndrome named epilepsy. This disease may affect people
of all ages. In recent years, an immense interest has been
generated in the search of herbal drugs and formulations
that may be used in the treatment of epilepsy. Brahmi is
one such widely used herbal drug that alleviates nervous
function, enhances memory, and reduces convulsions and
inflammation. It has been reported that CDRI-08 (KeenMind)
produces anticonvulsive action (Reas et al., 2008). Paulose
et al., studied the role played by metabotropic glutamate-8
receptor (mGluR8) and NMDA receptor 1 (NMDAR1) gene
expression in pilocarpine induced epilepsy and during neonatal
hypoxia (Paulose et al., 2008). During epilepsy, mGluR8 gene
was downregulated whereas NMDAR1 gene showed increased
expression in hypoxic neonates. To explore the neuroprotective
role of Brahmi, epileptic rats were supplemented with the herbal
medication and hypoxia induced rats were supplemented with
glucose, oxygen and epinephrine. The findings revealed that
Brahmi treatment significantly reversed the downregulation of
mGluR8 gene to normal level. Similarly, glucose supplementation
together with oxygen supply in hypoxic neonates rescued the
NMDAR1 gene expression to normal level. These observations
suggest a neuroprotective role of Brahmi in glutamate-mediated
excitotoxicity during seizures in pilocarpine-induced epilepsy.
A study employed a number of convulsion inducing models
including pentylenetetrazol, strychnine, hypoxic stress and
pilocarpine to investigate the anticonvulsive activity of Brahmi in
rats and mice. Brahmi was administered orally (50 and 55mg/kg)
in these animals, 2 and 4 h prior to receiving convulsive stimuli.
It was found that the herb produced a significant anticonvulsant
activity like benzodiazepines in different convulsion inducing
models studied (Kaushik et al., 2009).
CDRI-08 (KeenMind) has been reported to ameliorate
pilocarpine induced epilepsy through regulation of 5-HT2C
and NMDA receptors in cerebral cortex (Khan et al., 2008;
Krishnakumar et al., 2009a,b, 2015). During epileptic condition,
the expression of glutamate receptors is altered. 5-HT2C
receptor and IP3 (a signal transduction molecule) shows
an elevated expression during epileptic state. On the other
hand, NMDA receptor shows a downregulated expression in
the brain of epileptic animals whereas mGlu5 and GLAST
shows an upregulated expression leading to glutamate mediated
excitotoxicity. It has been shown that treatment of epileptic
rats with Brahmi reverses the changes observed in 5-HT2C,
NMDA receptor expression and IP3 content thereby effectively
managing the neurotransmitter balance in the cerebral cortex.
These observations suggest the neuroprotective role of CDRI-08
(KeenMind) in glutamate-mediated excitotoxicity via regulating
altered neurotransmitter receptor expression during seizures
observed in pilocarpine induced epilepsy.
Antidepressant Effects
Brahmi appears to play a plethora of functions in the central
nervous system. In addition to its diverse role in treating the
diseased brain, the herb shows anti-depressant property. When
mice supplemented with CDRI-08 (KeenMind) were subjected
to tail suspension test (TST) and forced swimming (FST),
the herbal drug exerted antidepressant activity (Shen et al.,
2009). The drugs were given orally for 5 days that significantly
minimized the immobility time span both in FST and TST.
The antidepressant activity of Brahmi was believed to have
occurred by some of its components like Bacosides A and B,
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bacopasaponin C, bacopasides I and II and its plant extract.
However, bacopaside VII, a constituent of Brahmi, did not reveal
any antidepressant activity when analyzed using tail suspension
and forced swimming tests (Sairam et al., 2002; Sheikh et al.,
2007; Zhou et al., 2007). Banerjee et al. investigated whether
treatment with Brahmi produces any antidepressant activity
in rats which were made to undergo chronic unpredictable
stress based depression (Banerjee et al., 2014). The group used
some behavioral tests like sucrose consumption test, shuttle box
escape test and open field test to validate this hypothesis. Stress
was induced in rats for a period of 4 weeks. This resulted
in decreased consumption of sucrose, locomotor activity and
escape latency in the animals. In addition, both mRNA and
protein content of brain-derived neurotrophic factor (BDNF)
showed downregulated expression in both the frontal cortex and
hippocampus in CUS treated rats. Supplementation with Brahmi
(80–120mg/kg) greatly suppressed the behavioral changes and
attenuated BDNF content to normal in the frontal cortex and
hippocampus areas of the rat brain confirming its antidepressant
activity.
The antidepressant activity of Brahmi was reported in
morphine induced depression in rats (Rauf et al., 2014).
Morphine, an opioid analgesic drug, when administered in rats
cause depression. The drug was administered everyday two times
at a dose of 20–65mg/kg for 8 consecutive days. Three days after
last morphine administration forced swimming test (FST) was
conducted to assess the withdrawal effect of the drug. It was
found that Brahmi treatment inhibited the withdrawal effect of
the morphine induced depression. Altogether, Brahmi can be
considered as a useful adjunct to cure depression like illnesses.
Antianxiety Effects
CDRI-08 (KeenMind) possess antianxiety effects, antidepressant
activity, anticonvulsive action and antioxidant activity (Reas
et al., 2008). Supplementation of Brahmi normalized the levels of
corticosterone hormone which were imbalanced due to acute and
chronic stress induction in rats. The levels of 5-HT, noradrenalin
(NA) and dopamine in cortex and hippocampus regions of rats
were also brought to normal in acute and chronic unpredictable
stress induced animals (Sheikh et al., 2007). Brahmi modulates
the cholinergic system and produces metal chelating effects.
Cognitive abnormalities produced by neurotoxins, colchicine
and ibotenic acid were improved by Brahmi administration in
a dose dependent manner in rats (Bhattacharya et al., 2000;
Rauf et al., 2012b). Also norepinephrine levels declined and
5-hydroxytryptamine levels were increased in hippocampus,
cerebral cortex and hypothalamus by Brahmi treatment. Anxiety
was relieved to a greater extent with higher doses of CDRI-08
(KeenMind), which was comparable to lorazepam, a standard
drug used in the treatment of anxiety (Bhattacharya and
Ghosal, 1998). However, treatment with lower dose of CDRI-08
(KeenMind; 10, 20, or 30mg/kg supplemented for 1 week period)
did not affect serotonin (5-HT) and dopamine levels in mice
brain (Rauf et al., 2012b).
Antioxidant Effects
Oxidative stress and subsequent formation of free radicals has
been implicated in the development of several diseases. Brahmi,
a traditionally reputed herbal drug, has been reported to exert
antioxidant activity. There are many factors that produce free
radical mediated oxidative stress in vivo. Smoke formed from
crackers increases the risk of the development of many lung
diseases that ultimately results in the formation of oxidative
stress. Pandareesh M. and Anand assessed whether Brahmi
ameliorates the neuronal damage and physiological changes in
rats upon smoke exposure (Pandareesh M. and Anand, 2014).
The group exposed the rats to smoke for 1h for 3 weeks and
treated the animals with Brahmi with three different dosages
viz., 10, 20, and 40mg/kg body weight. This treatment quenched
reactive oxygen species formed as a result of smoke exposure
and normalized the pathological changes observed in rat brain.
Also, the rate of acetylcholine esterase activity, lipid peroxidation
and brain neurotransmitter levels were found to be normal
upon Brahmi treatment. The herb also down regulated iNOS
expression thereby inhibited nitric oxide generation and HO-1
expression. Antioxidant enzyme concentration and monoamine
oxidase activity were also enhanced which were depleted upon
smoke exposure. These findings suggest the antioxidant and
neuroprotective properties of Brahmi and may be considered as
a possible remedy in the treatment of several neurodegenerative
disorders.
Furthermore, oxidative stress generated by lead exposure is
ameliorated by Brahmi in various areas of rat brain (Velaga
et al., 2013). Lead exposure raised the levels of reactive oxygen
species (ROS). Also the rate of lipid peroxidation, the carbonyl
content in total protein and metal content in different tissues
of rat brain. However, Brahmi treatment mitigated the levels
of these proteins to normal suggesting its antioxidant property.
Similarly, oxidative stress generated by sodium nitroprusside
(SNP) was ameliorated by Brahmi treatment in PC12 cells
(Pandareesh M. D. and Anand, 2014). In this study, Brahmi
inhibited the generation of NO via down regulating iNOS
expression. Heat shock proteins together with apoptotic markers
such as Bax, Bcl-2, cytochrome-c and caspase-3 were also
modulated to normal, the level of which was imbalanced by SNP
exposure in PC12 cells. In addition, sodium nitroprusside (SNP)
induced damage to plasma membrane, nuclear membrane and
mitochondrial integrity of PC12 cells was ameliorated by Brahmi
treatment. These findings suggests a protective and antioxidant
role Brahmi exhibits to PC12 cells by mitigating the SNP induced
toxicity.
Brahmi also ameliorates decabrominated diphenyl ether
(PBDE-209) provoked toxicity in neonate and young female
mice (Verma et al., 2014). Different doses of Brahmi (40, 80,
or 120mg/kg) in combination with PBDE-209 (20mg/kg body
weight) were administered orally in mice from postnatal day 3
to day 10. Levels of oxidative stress indicators (malondialdehyde,
and protein carbonyl) and antioxidant markers (superoxide
dismutase and glutathione peroxidase) were measured. The
results showed that the dose of 120mg/kg of Brahmi restored
the levels of oxidants and activities of antioxidant enzymes in
the hippocampus and frontal cortex of neonates against PBDE-
209-induced toxicity. This data suggests that Brahmi renders
the brain resistant to PBDE-209 induced toxicity and thus may
be better exploited as a preventive approach to protect against
oxidative-mediated neuronal dysfunctions.
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Another paraquat (PQ) mediated oxidative stress and
neurotoxicity was ameliorated by Brahmi treatment in different
brain regions of pre-pubertal mice (Hosamani et al., 2014). Mice
were administered CDRI-08 (KeenMind) daily (200mg/kg body
weight) for 4 consecutive weeks along with PQ (15mg/kg body
weight, intraperitoneally) after 3 h of last dose of extract.Within 2
days PQ administration resulted in the up regulation of oxidative
stress indicating molecules (such as reactive oxygen species
(ROS), hydroperoxides (HP) and malondialdehyde (MDA).
However, Brahmi restored PQ induced oxidative stress back
to normal via suppression of these markers in various brain
regions.
Previous studies have demonstrated increased reactive oxygen
species formation and cytotoxicity in cells exposed to hydrogen
peroxide (H2O2). Hence, H2O2 has been greatly used to study the
effects of antioxidant and cytoprotective role of herbal extracts.
Pandareesh et al. studied the effect of Brahmi on H2O2mediated
oxidative stress in PC12 and L132 cells (Pandareesh et al., 2014).
In this study, cells were treated with H2O2 for 24 h with or
without Brahmi pretreatment. A couple of tests including cell
viability assay, ROS estimation, lipid peroxidation, mitochondria
membrane potential assay, comet assay and gene expression
studies were conducted to measure the cytoprotective activity
of Brahmi. Brahmi scavenged free radicals formed during the
process thereby assisting in cytoprotection. Moreover, H2O2
induced mitochondrial and plasma membrane damage was
repaired by Brahmi in both of these cell lines.
Stress is a common and sometimes unavoidable problem that
may lead to serious health effects. Investigators are attempting
to explore the role of phytochemicals, plant extracts and
compounds in modulating the activities of stress associated
biomarkers. The levels of stress biomarkers namely Hsp, SOD,
and cyt P450 were evaluated to study the effect of Brahmi
in stress induced animals. To investigate the antistress effect,
the herbal medicine was orally administered (20 and 40mg/kg)
in rats for 7 successive days (Chowdhuri et al., 2002). Stress
induction elevated Hsp expression in brain. However, the protein
expression remain unaltered at both doses of Brahmi in all brain
regions. Interestingly, pretreatment of animals with Brahmi (7
days period) before stress induction resulted in decreased Hsp
expression in all brain areas with more significant reduction in
hippocampus region. At the same time, lower dose of Brahmi
decreased SOD activity whereas its higher dose increased it in
the hippocampus region of the rat brain. Similarly, pretreatment
with a lower dose of Brahmi further reduced the SOD activity
in each of the brain regions. However, higher dose of Brahmi
led to elevation in the enzyme activity in all areas of the
brain except cerebellum and hippocampus where it dropped
significantly. Similarly stress increased the activity of Cyt P450
in all the brain regions. Almost similar results were observed
with both the doses, but the P450 expression reduced with a
higher dose of Brahmi. Likewise, animals pretreated with the
higher dose of Brahmi followed by stress induction restored the
activity of P450 enzymes to near normal levels in animals. These
findings indicated the effectiveness of Brahmi in regulating stress
biomarker levels and suppoting the brain to combat stressful
conditions.
Mathur et al. employed DPPH radical scavenging method
to investigate the antioxidant nature of four different extracts
of CDRI-08 (KeenMind) in male wistar rats. It was found
that all the four different extracts possessed the maximum
antioxidant activity (Mathur et al., 2010). Brahmi has also
been considered as a valuable supplement in the treatment
of cancer and tumor. Janani et al. studied the effects of
Brahmi on chemoprevention of liver cancer in an animal model
(Janani et al., 2010). The group treated the animals with a
carcinogen, which led to an increase in their lipid peroxidation,
tumor biomarkers and markers corresponding to liver damage.
Eventually, hemolysate and antioxidant status dropped markedly
in the liver. Brahmi supplementation recovered the enzyme
levels to normal, suppressed lipid peroxidation and enhanced
its antioxidant status suggesting its chemoprotective role in
the treatment of liver cancer. Similarly, the antioxidant and
tumor inhibiting property of Brahmi was studied in 3-
methylcholanthrene induced fibrosarcoma rats (Rohini et al.,
2004). The levels of the antioxidant enzymes such as glutathione
peroxidase, superoxide dismutase, catalase and glutathione, the
rate of lipid peroxidation (LPO) were determined in the liver and
kidney tissues. Sarcoma induction in rats resulted in a marked
increase in the rate of LPO and a decrease in the antioxidant
enzyme status. Furthermore, tumor markers such as lactate
dehydrogenase, alanine transaminase, aspartate transaminase,
creatine kinase, and sialic acid showed an upregulated expression
in the serum. Brahmi supplementation enhanced the antioxidant
enzyme status, reduced the rate of lipid peroxidation and
downregulated tumor development markers.
Similar to many previous reports, an investigating group
measured the antioxidant and lipid peroxidative status in
response to Brahmi supplementation in streptozotocin induced
diabetic rats. They provided CDRI-08 (KeenMind) orally to
these diseased animals daily for 15 days (dosage: 50, 125,
and 250mg/kg). Thereafter, the enzymatic activity of catalase,
SOD and GPx, levels of GSH and rate of lipid peroxidation
were measured in kidney and brain, with special attention
to cerebrum, cerebellum and midbrain. It was found that
antioxidant status and peroxidative damage was totally reversed
by the administration of plant extract. Activities of SOD, catalase,
GPx and levels of GSH were significantly increased in diabetic
rats treated with extract (Kapoor et al., 2009). To investigate
the antidiabetic effect of this herb, Ghosh et al., treated alloxan
induced hyperglycemic rats with CDRI-08 (KeenMind). They
found that blood glucose level went down when single and
multiple doses of Brahmi were provided to the animals. Weight
of the rats was also recovered to normal with Brahmi treatment
which was lost during diabetes. CDRI-08 (KeenMind) also
inhibited the increase in glycosylated hemoglobin in vitro and
reduced thiobarbituric acid reactive substances (TBARS) content.
It also increased the levels of glutathione, SOD, catalase activity
in liver of diabetic rats. The effect of extract was such that the
peripheral glucose utilization was found to be increased in vitro
in the diaphragm of diabetic rats, which was proportionate to
the effect of insulin (Ghosh et al., 2010). The effects of CDRI-
08 (KeenMind) (40mg/kg) were studied on aluminum induced
oxidative stress and hippocampus damage in rats (Nannepaga
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et al., 2014). Electron microscopy was used to evaluate any
structural changes occurred as a result of aluminum intoxication
in the hippocampus region of the rat brain. The enzyme activities
of antioxidants such as catalase, glutathione peroxidase and SOD
were determined. Aluminum administration induced oxidative
damage, which was confirmed by finding increased levels of
thiobarbituric acid reactive substances in the rat brain. Treatment
with Brahmi for a period of 1 month decreased the levels of
thiobarbituric acid reactive substances, and restored antioxidant
enzyme levels. Furthermore, electron microscopy results of
Brahmi treated rats revealed attenuated vacuolation, lipofuscin
deposition and pyramidal cell degeneration in the hippocampus
which was induced via aluminum induction. These findings
further demonstrate Brahmi an important supplement useful for
ameliorating the antioxidant status and inhibiting the oxidative
damage occurred in aluminum intoxicated animals.
An in vitro study exploring the potential of Brahmi in
cytokine regulation, quenching of reactive oxygen species (ROS),
and ameliorating intracellular signaling pathway markers was
conducted in splenocytes of F344 rats (different age groups;
Priyanka et al., 2013). Firstly, concanavalin exposure induced
proliferation of lymphocytes acquired from spleen of F344 rats of
specific age groups (3-month-old, 8–9 month old, and 18 month
old). These proliferated splenocytes were thereafter treated with
different dosages of Brahmi (0.001, 0.01, 0.05, 0.1, and 1%)
and donepezil (5, 10, 25, 50, and 100µg/ml). The effect of
these drugs was studied via measuring the levels of cytokines,
antioxidant markers and different intracellular molecules. It
was found that donepezil alone but not Brahmi reduced the
lymphocyte proliferation in young rats. Cytokines such as IL-
2 and IFN-γ showed elevated expression with lower doses of
Brahmi whereas their expression reduced due to donepezil in
rats which were young and early middle-aged. Concanavalin
exposure also reduced the activity of antioxidant markers (SOD,
CAT, GPx, andGST) in these cells. On the contrary, enhancement
in CAT activity was observed in all age groups with Brahmi
supplementation whereas in older rats donepezil increased the
SOD activity. Likewise the action of GPx and GST biomarkers
was enhanced in lymphocytes via both Brahmi and donepezil
administration all age groups. Whereas in splenocytes there
was an enhancement in the rate of lipid peroxidation and
age-related suppression in NO generation. Brahmi along with
donepezil raised up NO production in the lymphocytes of
early middle-aged and older rats. It is important to note that
donepezil could suppress lipid peroxidation splenocytes of only
old rats whereas Brahmi could do the same in both early-middle-
aged and old rats. Similarly the reversal in decline of the p-
Akt expression was achived by Brahmi in both early middle
aged and old rats’ lymphocytes. We can conclude that Brahmi
alongwith donepezil exert various age-related effects on cytokine
generation, antioxidant status and intracellular targets whichmay
further manipulate the therapeutic efficiency of these drugs in
various diseases.
Gastrointestinal and Hepatoprotective
Effects
Brahmi has been shown to cure a number of gastrointestinal
disorders. A dose of 500mg/kg of CDRI-08 (KeenMind) when
supplied orally prevented the development of diarrhea in mice.
As compared to loperamide (50mg/kg) Brahmi was able to
decrease the frequency of defecation suggesting its role as an
anti-diarrhoeal herb (Siraj et al., 2012). Also, the fresh juice of
this herbal medicine has been shown to prevent the formation
of ulcers (Rao et al., 2000). In this study, the group assessed
the prophylactic and healing effects CDRI-08 (KeenMind) exerts
in five different models of gastric ulcers. It was found that
the extract (20mg/kg for 10 consecutive days) alleviated acetic
acid induced penetrating ulcers, strengthened mucosal barrier
and reduced mucosal exfoliation by reducing the rate of lipid
peroxidation in gastric mucosa of rat. The extract has also been
reported to produce anti-Helicobacter pylori activity (Sairam
et al., 2001; Goel et al., 2003). A randomized, double-blind,
placebo controlled clinical trial of 169 irritable bowel syndrome
patients, was conducted to assess the therapeutic capacity of an
Ayurvedic preparation containing Brahmi and Aegle marmelos
herbs. These herbal drugs were provided orally to the patients
three times daily for a period of 6 weeks. The effect of ayurvedic
treatment was highly beneficial in curing the disease. However,
the extent of Brahmi’s efficacy could not be predicted as both the
drugs were given at the same time to the patients (Yadav et al.,
1989).
CDRI-08 (KeenMind) has been found to exert
hepatoprotective effect in rats by alleviating antioxidant
enzymes status induced by morphine (Sumathi et al., 2011). It
was found that morphine induction increased the rate of lipid
peroxidation and decreased antioxidant enzyme status in rats.
This toxicity induced as a result of morphine induction was
nullified by the supplementation of Brahmi.
Endocrine Effects
The potential of Brahmi in treating endocrine related
abnormalities has been documented in a few animal studies.
CDRI-08 (KeenMind; 200mg/kg orally) has been shown to
alter the secretion of thyroid hormone in male mice (Kar et al.,
2002). The synthesis of T4 hormone was increased by 41% via
Brahmi intake. However, T3 synthesis was unaffected by the drug
supplement indicating that the drug might not be involved in T4
to T3 conversion. Furthermore, Brahmi has been demonstrated
to possess the anti-fertility ability in male mouse (Singh and
Singh, 2009).
Antimicrobial Effects
Methanolic extracts of CDRI-08 (KeenMind) have been reported
to possess antimicrobial activity as compared to other extracts
(Azad et al., 2012; Katoch et al., 2014). In this study, hexane
and petroleum ether extracts inhibited the growth of microbes
in a similar manner but the effect was less considerable
in comparison to methanolic extracts whereas the aqueous
extract of CDRI-08 (KeenMind) did not show anti-microbial
activity (Hosamani et al., 2014). The growth of Staphylococcus
aureus was inhibited to a greater extent by the methanolic
extract (1mg/ml) of CDRI-08 (KeenMind) in comparison to
Salmonella typhi and Eschirichia coli. However, the extract did
not suppress the growth of K. pneumonia microbe (Rohini et al.,
2004).
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Anti-Inflammatory and Painkiller Effects
Brahmi, known for its anti-inflammatory and pain relieving
effects, acts by selectively inhibiting cyclo-oxygenase-2 enzyme,
and consequently reducing prostaglandins synthesis. Jain et al.
demonstrated that CDRI-08 (KeenMind) could effectively
suppress the experimentally produced inflammatory reaction
by quenching the synthesis of prostaglandins and preventing
lyosomal membranes from rupture. Also, treatment with
anti-inflammatory dose of Brahmi didn’t cause any gastric
problems (Jain et al., 1994). Writhing produced by acetic acid
in mice was reduced using whole plant ethanol extract of
CDRI-08 (KeenMind) (250 and 500mg/kg; Rao et al., 2000).
Mathur et al. used different extracts of CDRI-08 (KeenMind)
and studied their anti-inflammatory effects in edema caused
by carrageenan in rat’s hind paws. Supplements including
methanolic and aqueous extract (100mg/kg) of Brahmi were
found to significantly reduce inflammation, while, petroleum
ether and hexane extracts produced no effect (Janani et al.,
2010). Also, it was found that methanolic extract (100, 200,
300µg) assisted in membrane stabilization as compared to
diclofenac sodium (Rohini et al., 2004). Interleukin-6 and tumor
necrosis factor-alpha synthesis was inhibited by the fractions
of Brahmi containing triterpenoids and bacosides (Viji and
Helen, 2011). Furthermore, proinflammatory cytokines such as
nitric oxide and TNF-α showed down regulated expression
in stimulated macrophages and IFN-γ in stimulated human
blood cells (Williams et al., 2014). These results provide further
evidences that confirm the efficacy of Brahmi in the treatment of
brain inflammation.
Relaxant Effects on Smooth and Cardiac
Muscles
Investigations exploring the potential of CDRI-08 (KeenMind)
in relaxing cardiac and smooth muscles have been demonstrated
in experimental animals. The herbal extract ameliorates left
ventricular contractility, coronary blood flow and heart rate
in rabbit’s heart (Rashid et al., 1990). It also relaxes bronchial
smooth muscles, pulmonary arteries, aorta, and trachea.
Apparently, the mechanism of action Brahmi exerts on the
cardiac muscles is quite similar to that of quinidine. These effects
possibly were mediated by accumulation of calcium ions in the
extracellular space (Dar and Channa, 1997, 1999; Channa et al.,
2003). Furthermore, CDRI-08 (KeenMind) stabilizes the activity
of mast cells comparable to disodium cromoglycate (Samiulla
et al., 2001).
CLINICAL TRIALS
Traditionally Brahmi is known to ameliorate cognitive function.
This viewpoint has now been scientifically tested through a
handful of randomized, double-blind, placebo-controlled clinical
trials and nearly all have shown promising results. (Singh et al.,
2014) found that supplementation of 12g of Brahmi improved
the nervousness, concentration and memory in adults. The dose
was given to 35 adults in the form of syrup for 4 weeks. There
was no complaint of side effects (Singh and Singh, 1980). Similar
observations were confirmed by Sharma et al. who studied the
effect of Brahmi in 20 primary school children (Sharma et al.,
1987). A dosage of 350mg was given in syrup form three
times a day for 3 months. The herb improved learning skills,
perception, memory and reaction times in them without the
occurrence of any side effects. A randomized and double-blind
placebo-controlled trial in 36 children was conducted, who were
affected with attention deficit hyperactivity disorder (ADHD)
was conducted (Negi et al., 2000). The results were highly
beneficial with Brahmi supplementation as it greatly improved
the logical memory. In this study, freshly preperaed whole plant
extract of Brahmi was administered at a dosage of 50mg two
times a day for a period of 12 weeks. Later, cognitive function
tests were performed at various time points which included
baseline, 4, 8, 12, and 16 weeks. Recovery was observed in the 12
weeks group, consolidated by different cognitive tests. A placebo
controlled study demonstrated enhanced learning and controlled
abnormal behavior in 40 mentally retarded children consuming
standardized extract of CDRI-08 (KeenMind; Dave et al.,
1993). Another randomized, double-blind, placebo-controlled
trial proved the effectiveness of Brahmi in ameliorating memory
(Roodenrys et al., 2002). In this study, 76 healthy adults, 40–65
years old, were supplemented with Brahmi (dose 300mg) and
they all were benefitted by retaining the information in delayed
recall of word pairs. However, there were a few parameters
which failed to show the beneficial effect of Brahmi. These
include attention, working memory, short-term memory tasks,
psychological state and retrieval of prior knowledge. Likewise, no
effect of Brahmi (300mg dosage) on variousmeasures of memory
performance was found when it was administered 2 h after
treatment suggesting that its benefits are obtained after long-term
use (Nathan et al., 2001). The same group of investigators later
found no significant effect of Brahmi (300 mg/day) on cognition
and memory when provided in combination with Ginko biloba
120mg/day for a period of 4 weeks. This was a randomized,
placebo-controlled, double-blinded clinical trial, conducted in 85
healthy subjects (Nathan et al., 2004). BacomindTM capsule when
consumed orally (at a dose of 300mg once a day for first 15
days and 450mg once a day for next 15 days) improved mental
functioning in 23 healthy adults (Pravina et al., 2007).
A placebo-controlled and double-blinded 12-week clinical
trial was carried out to investigate the effectiveness of CDRI-08
(KeenMind) (300mg daily for 12 weeks) on 46 healthy people
aged between 18 and 60 years. A series of cognition function tests
were conducted at baseline and later on after 5 and 12 weeks.
At the end of 12 weeks, in the treatment group a significant
enahncement in verbal learning and concentration was noticed
compared to non-treated groups. These effects were not observed
at baseline or at 5 weeks of treatment (Stough et al., 2001).
Likewise many other clinical trials were conducted to determine
the effect of Brahmi on memory function in elderly people above
the age of 55 years. They all used same criteria with same amount
of dosage and period of administration. It was found that aged
people were able to acquire, store and retain their memory
over time by consuming Brahmi as a supplement (Calabrese
et al., 2008; Morgan and Stevens, 2010). Another randomized
double-blind placebo-controlled clinical trial examining the
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TABLE 1 | Clinical trials of Brahmi.
Study
design
Subjects Dosage of
Brahmi/day
Time span of the
drug
administration
Results References
– 35 adults 12 gm/day 4 weeks Reduced anxiety, enhanced memory span
and concentration.
No side effects observed.
Singh and Singh, 1980
– 20 primary school
children
350mg × 3/day 3 months Enhanced memory, learning, perception and
reaction times. No side effects observed.
Sharma et al., 1987
PC 40 Mentally
retarded children
with or without
epilepsy
CDRI-08 (KeenMind) – Enhanced learning and controlled abnormal
behavior.
Dave et al., 1993
RA, DB,
PC
36 children with
Attention deficit
hyperactivity
disorder (ADHD)
50mg × 2/day 12 weeks Ameliorated various cognitive assessments.
No side effects observed.
Negi et al., 2000
– 38 healthy
subjects
300 mg/day 2 h post
administration
No improvement in memory performance. Nathan et al., 2001
DB, PC 46 healthy people 300 mg/day 12 weeks Improved early information processing and
verbal learning rate. Consolidated memory
and reduced state anxiety. Side effects:
nausea, dry mouth and fatigue.
Stough et al., 2001
RA, DB,
PC
76 healthy adults 300 mg/day 12 weeks Enhanced retention of new information. Roodenrys et al., 2002
RA, DB,
PC
85 healthy
subjects
Combination of
standardized CDRI-08
(KeenMind) 300 mg/day
and Ginko biloba 120
mg/day
4 weeks No significant effect on cognition and
memory.
Nathan et al., 2004
RA, OL,
DE
23 healthy adult
volunteers
BacomindTM capsule
300 mg/day and 450mg
15 days each,
respectively
Improved cognition. Minor gastrointestinal
adverse effects.
Pravina et al., 2007
RA, DB,
PC
54 healthy adults Standardized CDRI-08
(KeenMind) 300 mg/day
12 weeks Enhanced cognitive performance in the
aging.
Calabrese et al., 2008
RA, DB,
PC
98 healthy adults BacomindTM capsule
300mg
12 weeks A significant improvement in memory
acquisition and retention was observed.
Gastrointestinal side effects reported.
Morgan and Stevens,
2010
RA, DB,
PC
465 participants 300 mg/day 12 months Improvement in memory function. Stough et al., 2012
RA, DB,
PC
60 healthy adults 300 mg/day 12 weeks Attention, cognitive processing, and working
memory improved.
Peth-Nui et al., 2012
RA, DB,
PC
109 healthy
subjects and 123
SDAT patients
500mg × 2/day 12 months Improvements in memory performance and
reduction in the levels of inflammatory and
oxidative stress markers observed in Brahmi
treated SDAT patients.
Sadhu et al., 2014
PC, NC,
MC
104 elderly
subjects with mild
cognitive
impairment
1 Illumina® tablet/day 60 days Cognitive function improved. One non
serious adverse effect reported.
Zanotta et al., 2014
DB, PC 17 healthy
volunteers
320mg and 640mg Brahmi supplementation reduced stress and
alleviated mood in these participants.
Benson et al., 2014
RA, Randomized; DB, Double-blind; PC, Placebo-controlled; OL, Open label; DE, Dose escalation; PC, Prospective cohort; NC, Noncomparative; MC, Multicenter.
effect of Brahmi on cognitive, biochemical and cardiovascular
performance was conducted in elderly people (Morgan and
Stevens, 2010). This study involved a large number of randomly
selected participants (465 participants) aged between 60 and 75
years. CDRI-08 (KeenMind) (300mg/day) was given to them for
a period of 12 months. The participants underwent a series of
cognitive function tests at points: baseline, 3, 6, and 12 months
and expectedly, the results revealed a significant improvement
in their memory function which suggests the effectiveness of
Brahmi to be used as a memory booster.
Peth Nui et al. tested different aspects of brain function like
attention, cholinergic and monoaminergic functions, memory
processing and working memory-using Brahmi. They recruited
60 healthy adults aged around 60 years for a randomized,
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double-blind, placebo-controlled clinical trial. The period of
Brahmi administration and dosage was similar to previous
studies (300mg for 12 weeks; Peth-Nui et al., 2012). AChE
and MAO activities were measured to evaluate the cholinergic
and monoaminergic systems functions. On the contrary, percent
accuracy and reaction time was examined to determine the
working memory. Latencies and amplitude of N100 were used
to measure attention and cognitive processing. The findings
of this study revealed a reduction in both N100 and P300
latencies and improvement on working memory with Brahmi
supplementation. Furthermore, AChE activity was also found to
be decreased suggesting that Brahmi can ameliorate cognitive
processing, working memory and attention partly through the
reduction of AChE activity. In another similar kind of clinical
trial involving healthy elderly subjects and others suffering
from senile dementia of Alzheimer’s type (SDAT), behavioral
and biochemical parameters like learning abilities, inflammatory
markers and oxidative stress were measured (Sadhu et al., 2014).
A number of cognitive function tests were employed after every
3 months to evaluate the potential of Brahmi in these people.
It was found that Brahmi treated SDAT patients improved
memory performance when compared to controls. The levels
of inflammatory markers like homocysteine, C-reactive protein,
and tumor necrosis factor alpha; oxidative stress markers like
glutathione peroxidase, glutathione, thiobarbituric acid reactive
substances and SOD showed a marked decline in Brahmi treated
SDAT patients. This suggests the significance of the herb in
managing cognitive decline associated with the aging process.
Another multicenter clinical trial involving patients with mild
cognitive impairment used similar criteria and obtained favorable
results establishing the role of Brahmi in improving cognitive
function (Zanotta et al., 2014).
Recently, the acute effects of Brahmi (320 and 640mg
doses) on stress and mood swings generated by multitasking
were demonstrated in a double-blind, placebo-controlled clinical
trial involving 17 healthy volunteers (Benson et al., 2014).
Brahmi supplementation reduced stress as observed by reduction
in cortisol levels and alleviated mood in these participants.
Altogether, these studies demonstrate the therapeutic efficacy
of Brahmi in alleviating various abnormalities hence can be
considered as a promising frontier to treat various diseases.
Table 1 indicates clinical trials of Brahmi.
FUTURE DIRECTIONS
The therapeutic effects of Brahmi have been extensively
investigated by various research groups. It is believed that
the bacosides, act as active constituents of the herbal extract
which are predominantly involved in exerting the nootropic
effects in both animals and humans. The delivery of active
components to brain itself is a challenging task, which can
be solved to great extend by nanoscience. As nanoscience has
emerged as a subject of significant curiosity which associated
with special properties like surface to volume ratio and surface
reactivity. Drug delivery to the brain represents one of the most
important challenges in the field of nanomedicine. At the same
time, a better understanding of the physiopathological nature
of different diseases associated to cognitive science and insight
into the interaction of nanomaterials with biological systems
at various levels (i.e., systemic, organ, tissue, and cell) are of
paramount importance for further progress toward bench-to-
bedside translation or the mechanisms underlying the effects
of Brahmi in various disease conditions need to be elucidated
extensively at the molecular level and followed by clinical trials.
In order tomake the extract/ active components targeted to brain,
use of targeted nanoparticles based on liposomes, polymeric
micelles, polymersomes can be considered as an important tool.
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